GlassScriptPhysician profile
Paul G Linder
NPI 1992709349
$54,366.47
in general payments reported to CMS, 2019-2025
18 companies · $736 in 2025
The $736 reported for 2025 was more than what 80% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $728 · 2020: $105 · 2021: $17K · 2022: $30K · 2023: $4,962 · 2024: $761 · 2025: $736.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $4,875 · Food and Beverage: $1,557 · Travel and Lodging: $26.20.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $4,875.00 |
| Food and Beverage | $1,557.13 |
| Travel and Lodging | $26.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $51,592.89 | 2021-2023 | |
| Astrazeneca Pharmaceuticals LP | $776.63 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $383.13 | 2019-2025 | Ozempic, Rybelsus |
| Pfizer INC. | $286.56 | 2019-2025 | |
| Inari Medical, INC. | $189.09 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Abbvie INC. | $165.79 | 2022-2024 | |
| Janssen Pharmaceuticals, INC | $157.33 | 2019 | |
| Amgen INC. | $156.98 | 2019 | |
| Pulmonx Corporation | $147.80 | 2024 | Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter, Chartis Catheter |
| Lilly USA, LLC | $127.46 | 2019-2025 | Jardiance, Zepbound, Mounjaro |
| Glaxosmithkline, LLC. | $82.47 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| E.R. Squibb & Sons, L.L.C. | $77.95 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $61.77 | 2020-2025 | Jardiance |
| Abbott Laboratories | $50.45 | 2022-2025 | Freestyle Libre 3 |
| Dexcom, INC. | $35.14 | 2023-2024 | Dexcom G6 Transmitter |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $30.60 | 2022 | |
| Daiichi Sankyo INC. | $25.55 | 2019-2020 | |
| Allergan, INC. | $18.88 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Linder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.